Countermeasures Against Chemical Threats (CounterACT) Research Centers of Excellence (U54 Clinical Trial Optional)
Funding Opportunity PAR-18-657 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages applications for Countermeasures Against Chemical Threats (CounterACT) Research Centers of Excellence (U54s). The mission of the CounterACT program is to foster and support research and development of new and improved therapeutics for chemical threats. Chemical threats are toxic chemicals that could be used in a terrorist attack or accidentally released from industrial production, storage or shipping. They include traditional chemical warfare agents, toxic industrial chemicals, pharmaceutica...
Source: NIH Funding Opportunities (Notices, PA, RFA) - February 13, 2018 Category: Research Source Type: funding
Lewy Body Dementia Center Without Walls (CWOW) (U54 Clinical Trial Not Allowed)
Funding Opportunity RFA-NS-18-024 from the NIH Guide for Grants and Contracts. This FOA invites applications that will systematically and comprehensively characterize alpha-synuclein and amyloid-beta subspecies present in human Lewy Body Dementia (LBD) post-mortem brain tissue, identify toxic subspecies and potential mechanisms of toxicity, and characterize any interactions between the proteins that may contribute to increased toxicity and/or explain selective vulnerabilities of cells/circuits. Applications are required to include at least 3 hypothesis-driven projects that address these goals, an administrative core, an...
Source: NIH Funding Opportunities (Notices, PA, RFA) - February 9, 2018 Category: Research Source Type: funding
Research on Comparative Effectiveness and Implementation of HIV/AIDS and Alcohol Interventions (R01 - Clinical Trials Optional)
Funding Opportunity PAS-18-557 from the NIH Guide for Grants and Contracts. HIV+ alcohol users remain at high risk for medication non-adherence and rapid disease progression, medication toxicities, organ failure, and poor viremic control, leading to increased risk of transmission and premature death. Recent advances in technology and biomedical science (e.g., new pharmacological agents, alcohol and inflammation biomarkers, internet and mobile technology) open new opportunities for strengthening the quality of HIV/alcohol-related implementation research through utilization of novel technology and biomarkers. This initiat...
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 2, 2018 Category: Research Source Type: funding
Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44) - Clinical Trial Optional
Funding Opportunity PAR-18-541 from the NIH Guide for Grants and Contracts. The Blueprint Neurotherapeutics Network (BPN) encourages applications from small businesses seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract resear...
Source: NIH Funding Opportunities (Notices, PA, RFA) - December 21, 2017 Category: Research Source Type: funding
Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3) - Clinical Trial Optional
Funding Opportunity PAR-18-546 from the NIH Guide for Grants and Contracts. The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract...
Source: NIH Funding Opportunities (Notices, PA, RFA) - December 21, 2017 Category: Research Source Type: funding
Microphysiological Systems Data Center U24 (Clinical Trial Not Allowed)
Funding Opportunity RFA-TR-18-005 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite cooperative agreement applications for the Tissue Chip Testing Center (TCTC) Microphysiological Systems (MPS) Data Center (MPS DC), which supports the NIH Tissue Chip Consortium. The Consortium facilitates the development, validation and dissemination of tissue chip (TC) technology through support for collaborative research in 1) development of tissue chips for toxicity and safety testing of promising therapeutics (RFA-RM-11-022); 2) development of tissue chips for diseas...
Source: NIH Funding Opportunities (Notices, PA, RFA) - December 20, 2017 Category: Research Source Type: funding
NextGen Tissue Chip Testing Centers: Validating Microphysiological Systems (U24 Clinical Trial Not Allowed)
Funding Opportunity RFA-TR-18-006 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for NextGen Tissue Chip Testing Center(s) (NextGen TCTC) that will provide resources and infrastructure for the validation of tissue chips being developed as part of the NIH Tissue Chip (TC) for Drug Screening Program or NIH Microphysiological Systems (MPS) Program. The MPS program supports a consortium of investigators developing accurate cellular and organ microsystems representative of human physiology for the evaluation of drug efficacy and toxicity (RFA-RM-11-022; RFA-TR-16...
Source: NIH Funding Opportunities (Notices, PA, RFA) - December 20, 2017 Category: Research Source Type: funding
Microphysiological Systems (MPS) for Modeling Diabetes (UG3/UH3 Clinical Trial Not Allowed)
Funding Opportunity RFA-DK-17-035 from the NIH Guide for Grants and Contracts. NIDDK requests applications to join a new research consortium "Microphysiological Systems (MPS) for Modeling Diabetes (MPS-MOD)". NIDDK will support the development and validation of human tissue chips that closely mimic the normal physiology of key metabolic tissues, including the pancreatic islet, liver, skeletal muscle, and white adipose tissue (WAT). Experimental designs for the MPS-MOD platforms should incorporate strategies to measure pathophysiological changes associated with metabolic disease, including the impact of immune cells on m...
Source: NIH Funding Opportunities (Notices, PA, RFA) - December 11, 2017 Category: Research Source Type: funding
Microphysiological Systems (MPS) for Modeling Diabetes (UG3/UH3 Clinical Trial Not Allowed)
NIDDK requests applications to join a new research consortium "Microphysiological Systems (MPS) for Modeling Diabetes (MPS-MOD)". NIDDK will support the development and validation of human tissue chips that closely mimic the normal physiology of key metabolic tissues, including the pancreatic islet, liver, skeletal muscle, and white adipose tissue (WAT). Experimental designs for the MPS-MOD platforms should incorporate strategies to measure pathophysiological changes associated with metabolic disease, including the impact of immune cells on metabolic dysfunction. Once developed, these multi-dimensional MPS-MOD platforms wi...
Source: NIDDK Funding Opportunities - December 11, 2017 Category: Endocrinology Source Type: funding
NIH-CASIS Coordinated Microphysiological Systems Program for Translational Research in Space (UG3/UH3) (Clinical Trials Not Allowed)
Funding Opportunity RFA-TR-18-001 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to promote the development of in vitro microphysiological systems in modeling human diseases and conditions that mimic the pathology in major organs and tissues in the human body, when exposed to the extreme environments of space, and the use of these models at the International Space Station-U.S. National Laboratory (ISS-NL) to facilitate the assessment of biomarkers, bioavailability, efficacy, and toxicity of therapeutic agents prior to entry into clinical trials. Funds from the NIH will be made available through...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 30, 2017 Category: Research Source Type: funding
NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
Funding Opportunity PAR-18-020 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports the development of new exploratory research in cancer diagnosis, treatment, imaging, symptom/toxicity, and prevention clinical trials; correlative studies associated with clinical trials; novel cancer therapeutic, symptom/toxicity, and preventive agent development, radiotherapy development activities, and mechanism-driven combinations; and innovative preclinical studies--including the use of new clinically-relevant models and imaging technologies--which could lead to first-in-human clinical tr...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 17, 2017 Category: Research Source Type: funding
Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
Funding Opportunity PAR-18-174 from the NIH Guide for Grants and Contracts. The goal of this Funding Opportunity Announcement (FOA) is to provide funding support for the pre-clinical and early stage clinical (Phase I) development ofsmall-molecule and biologic therapeutic agents that prevent Alzheimer's disease (AD), slow its progression or treat its cognitive and behavioral symptoms.Participants in this program will receive funding for therapy development activities such as medicinal chemistry, pharmacokinetics (PK), Absorption, Distribution, Metabolism, Excretion, Toxicology (ADMET), efficacy in animal models, formulat...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 8, 2017 Category: Research Source Type: funding
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 - Clinical Trials Not Allowed)
Funding Opportunity PAR-18-317 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support the validation of molecular/cellular/imaging markers and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This FOA also includes the validation of pharmacodynamic markers and markers of toxicity. Applicants should have assays that work on human samples and whose importance is well justified for development into clinical assays. As chemotherapies and/or ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - October 12, 2017 Category: Research Source Type: funding
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 - Clinical Trials Not Allowed
Funding Opportunity PAR-18-310 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the adoption and validation of molecular/cellular/imaging markers and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This FOA also includes the validation of pharmacodynamic markers and markers of toxicity. Applicants to this FOA must have an assay(s) whose performance has been analytically validated in specimens similar to those for the intended c...
Source: NIH Funding Opportunities (Notices, PA, RFA) - October 12, 2017 Category: Research Source Type: funding
Population-Based Model Organism Research for G x E Exploration in Complex Disease Outcomes (R01 Clinical Trial Not Allowed)
Funding Opportunity RFA-ES-17-009 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) will support research using population-based model organism resources for environmental health science and toxicology questions. This FOA is particularly interested in the interplay between environment, genetics, and epigenetics and the identification and understanding of host susceptibility to environmental exposures, relevant to human disease outcomes. (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - September 21, 2017 Category: Research Source Type: funding
